Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
Aditxt (NASDAQ: ADTX) has announced a virtual fireside chat on October 28, 2024, at 11:30 AM ET, featuring Aditxt CEO Amro Albanna, Evofem CEO Saundra Pelletier, and moderated by Dr. Drew Pinsky. The event will focus on:
- Aditxt's acquisition of Evofem
- Post-acquisition plans for Evofem
- Aditxt's approach to accelerating innovations
The chat will highlight Evofem's evolution into a multi-product women's health franchise, including the re-launch of Solosec® and the planned launch of the Mitomic Endometriosis Test (MET™) in mid-2025. Aditxt estimates it will require $19.3 million to fund the Evofem acquisition, including $1.8 million for merger consideration and $2.28 million for additional Evofem stock purchase by October 31, 2024. An additional $15.2 million is needed to satisfy Evofem's Senior Secured Note at closing.
Aditxt (NASDAQ: ADTX) ha annunciato un incontro virtuale il 28 ottobre 2024, alle 11:30 AM ET, con il CEO di Aditxt Amro Albanna, il CEO di Evofem Saundra Pelletier, e moderato dal Dr. Drew Pinsky. L'evento si concentrerà su:
- L'acquisizione di Evofem da parte di Aditxt
- Piani post-acquisizione per Evofem
- L'approccio di Aditxt per accelerare le innovazioni
La conversazione metterà in evidenza l'evoluzione di Evofem in un franchising per la salute delle donne con più prodotti, incluso il rilancio di Solosec® e il lancio previsto del Test per l'Endometriosi Mitomic (MET™) a metà del 2025. Aditxt stima che saranno necessari $19,3 milioni per finanziare l'acquisizione di Evofem, di cui $1,8 milioni per la considerazione di fusione e $2,28 milioni per l'acquisto aggiuntivo di azioni di Evofem entro il 31 ottobre 2024. Serviranno ulteriori $15,2 milioni per soddisfare la Nota Senior Secured di Evofem al momento della chiusura.
Aditxt (NASDAQ: ADTX) ha anunciado un chat virtual el 28 de octubre de 2024 a las 11:30 AM ET, con el CEO de Aditxt Amro Albanna, la CEO de Evofem Saundra Pelletier, moderado por el Dr. Drew Pinsky. El evento se centrará en:
- La adquisición de Evofem por parte de Aditxt
- Planes posteriores a la adquisición para Evofem
- El enfoque de Aditxt para acelerar las innovaciones
La charla destacará la evolución de Evofem hacia una franquicia de salud femenina de múltiples productos, incluyendo el relanzamiento de Solosec® y el lanzamiento previsto de la Prueba de Endometriosis Mitomic (MET™) a mediados de 2025. Aditxt estima que necesitará $19.3 millones para financiar la adquisición de Evofem, que incluye $1.8 millones para la consideración de la fusión y $2.28 millones para la compra adicional de acciones de Evofem antes del 31 de octubre de 2024. Se requieren otros $15.2 millones para satisfacer la Nota Senior Secured de Evofem en el cierre.
Aditxt (NASDAQ: ADTX)는 2024년 10월 28일 오전 11시 30분 ET에 Aditxt CEO Amro Albanna, Evofem CEO Saundra Pelletier와 Dr. Drew Pinsky가 진행하는 가상 대담을 발표했습니다. 이 이벤트는 다음에 초점을 맞춥니다:
- Aditxt의 Evofem 인수
- 인수 후 Evofem 계획
- 혁신 가속화를 위한 Aditxt의 접근 방식
이번 대담에서는 Evofem이 다수의 여성 건강 제품 프랜차이즈로 발전하는 과정을 강조할 것입니다. 여기에는 Solosec®의 재출시와 2025년 중반에 예정된 Mitomic Endometriosis Test (MET™) 출시가 포함됩니다. Aditxt는 EVOFEM 인수를 위해 $19.3 백만이 필요하다고 추정하며, 여기에는 합병 고려를 위한 $1.8 백만과 2024년 10월 31일 이전에 Evofem의 추가 주식 매입을 위한 $2.28 백만이 포함됩니다. Evofem의 Senior Secured Note를 마감 시점에서 충족하기 위해 추가로 $15.2 백만이 필요합니다.
Aditxt (NASDAQ: ADTX) a annoncé un chat virtuel le 28 octobre 2024 à 11h30 ET, avec le PDG d'Aditxt Amro Albanna, la PDG d'Evofem Saundra Pelletier, et modéré par le Dr. Drew Pinsky. L'événement se concentrera sur :
- L'acquisition d'Evofem par Aditxt
- Les plans post-acquisition pour Evofem
- L'approche d'Aditxt pour accélérer les innovations
La discussion mettra en lumière l'évolution d'Evofem vers une franchise de santé des femmes multi-produits, y compris le relancement de Solosec® et le lancement prévu du Test Mitomic contre l'Endométriose (MET™) à la mi-2025. Aditxt estime qu'il faudra 19,3 millions de dollars pour financer l'acquisition d'Evofem, dont 1,8 million de dollars pour la consideration de fusion et 2,28 millions de dollars pour l'achat d'actions supplémentaires d'Evofem avant le 31 octobre 2024. Un montant supplémentaire de 15,2 millions de dollars est nécessaire pour satisfaire la Senior Secured Note d'Evofem lors de la clôture.
Aditxt (NASDAQ: ADTX) hat einen virtuellen Kaminabend für den 28. Oktober 2024 um 11:30 Uhr ET angekündigt, an dem Aditxt-CEO Amro Albanna, Evofem-CEO Saundra Pelletier und moderiert von Dr. Drew Pinsky teilnehmen werden. Die Veranstaltung wird sich auf Folgendes konzentrieren:
- Die Übernahme von Evofem durch Aditxt
- Nachtragspläne für Evofem
- Der Ansatz von Aditxt zur Beschleunigung von Innovationen
Die Diskussion wird die Entwicklung von Evofem zu einer Multi-Produkt-Franchise für Frauengesundheit hervorheben, einschließlich der Wiederveröffentlichung von Solosec® und der geplanten Einführung des Mitomic Endometriose-Tests (MET™) Mitte 2025. Aditxt schätzt, dass es $19,3 Millionen benötigt, um die Evofem-Übernahme zu finanzieren, einschließlich $1,8 Millionen für die Fusionsbetrachtung und $2,28 Millionen für den zusätzlichen Aktienkauf von Evofem bis zum 31. Oktober 2024. Zusätzlich werden $15,2 Millionen benötigt, um die Senior Secured Note von Evofem bei Abschluss zu begleichen.
- None.
- None.
Event to Focus on the Status of the Acquisition, Plans Post-Acquisition for Evofem, and Q&A
This virtual fireside chat aims to provide an update on Aditxt’s acquisition of Evofem, outline post-acquisition plans, and discuss why Aditxt’s approach to accelerating innovations enables its programs to meet unmet health needs. During the session, Albanna and Pelletier will explore the potential to enhance the strategic vision for Evofem post-acquisition and how Aditxt’s support strategic, operational, and financial contributions, which seek to put Evofem in a position to achieve its goals.
Under Pelletier's leadership, Evofem is at the forefront of addressing these issues by advancing pioneering solutions like Phexxi® (lactic acid, citric acid and potassium bitartrate) —the only FDA-approved, hormone-free, on-demand contraceptive vaginal gel. The fireside chat will highlight the support of the Aditxt platform and Evofem's evolution into a multi-product women’s health franchise focusing on prevention, treatment, and monitoring. A key milestone in this journey has been Evofem’s acquisition of the global rights to Solosec® (secnidazole), an FDA-approved medication for treating trichomoniasis and bacterial vaginosis. The Evofem commercial team is preparing for the U.S. market re-launch of Solosec®, seeking to position it as a cornerstone in its treatment portfolio.
Additionally, the collaboration between Aditxt’s subsidiary, Pearsanta, Inc. (“Pearsanta”) and Evofem to launch the Mitomic Endometriosis Test (MET™) would be a significant step in establishing Evofem’s diagnostic and monitoring capabilities. Targeting a
Building on its current momentum, Evofem is seeking to advance the rollout of next-generation products, each carefully designed to close the existing gaps in women's health care and improve outcomes across diverse life stages.
Participants are encouraged to engage directly with our panel by submitting questions via text or video by October 25, 2024, at 5:00 PM ET to engagement@aditxt.com. Registration details are available here.
The Company estimates it will require approximately
About Aditxt, Inc.
Aditxt, Inc.® is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued and empowers collective progress.
Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.
For more information, www.aditxt.com.
Follow us on:
LinkedIn: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241021269601/en/
Media Relations Contact:
Mary O’ Brien
mobrien@aditxt.com
(516) 753-9933
Source: Aditxt, Inc.
FAQ
When is Aditxt hosting the virtual fireside chat about the Evofem acquisition?
Who are the key participants in the Aditxt virtual fireside chat?
What is the estimated cost for Aditxt (ADTX) to acquire Evofem?
What new product is Evofem planning to launch in mid-2025 as part of its collaboration with Aditxt (ADTX)?